Revvity (NYSE:RVTY – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it compare to its competitors? We will compare Revvity to similar businesses based on the strength of its risk, analyst recommendations, earnings, dividends, valuation, institutional ownership and profitability.
Profitability
This table compares Revvity and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revvity | 8.61% | 8.64% | 5.24% |
| Revvity Competitors | -539.78% | 77.25% | -13.56% |
Volatility and Risk
Revvity has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Revvity’s competitors have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
Insider and Institutional Ownership
86.7% of Revvity shares are owned by institutional investors. Comparatively, 54.3% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Revvity and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revvity | 0 | 13 | 6 | 0 | 2.32 |
| Revvity Competitors | 957 | 3183 | 5516 | 178 | 2.50 |
Revvity currently has a consensus price target of $133.86, indicating a potential downside of 15.80%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 1.66%. Given Revvity’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Revvity has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares Revvity and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Revvity | $2.86 billion | $241.20 million | 70.35 |
| Revvity Competitors | $2.28 billion | $55.88 billion | -7.53 |
Revvity has higher revenue, but lower earnings than its competitors. Revvity is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Dividends
Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Revvity pays out 12.4% of its earnings in the form of a dividend. As a group, “Life Sciences Tools & Services” companies pay a dividend yield of 8.1% and pay out 44.5% of their earnings in the form of a dividend.
Summary
Revvity competitors beat Revvity on 8 of the 15 factors compared.
About Revvity
Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company’s work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
